전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved261 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

LV20.19 CAR T cells (LV20.19 CAR T cells)

Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

MOv19-BBz CAR T cells (MOv19-BBz CAR T cells)

Metastatic Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Non Small Cell Lung Cancer

#MetastaticNonSmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCelladon CorporationPhase 2

MYDICAR Phase 1 (MYDICAR Phase 1)

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy

#IschemicCardiomyopathy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleCelladon CorporationPhase 2

MYDICAR Phase 2 (MYDICAR Phase 2)

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy

#IschemicCardiomyopathy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleAssistance Publique Hopitaux De…Phase 2

IPH2201 (Monalizumab, Monalizumab (IPH2201))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Assistance
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab (N-803 + Avelumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting

10 / 14 pages

← PreviousNext →